Replies to post #32092 on Marker Therapeutics Inc (MRKR)

[jobynimble]

10-Q filing: https://www.sec.gov/ix?doc=/Archives/edgar/data/1094038/000141057822001389/mrkr-20220331x10q.htm

8-K: https://www.sec.gov/ix?doc=/Archives/edgar/data/1094038/000110465922059849/tm2215298d1_8k.htm

[jobynimble]

FIRST QUARTER 2022 FINANCIAL RESULTS

Cash Position and Guidance: At March 31, 2022, Marker had cash, cash equivalents and restricted cash of $28.8 million.

R&D Expenses: Research and development expenses were $7.0 million for the quarter ended March 31, 2022, compared to $5.6 million for the quarter ended March 31, 2021.

G&A Expenses: General and administrative expenses were $3.7 million for the quarter ended March 31, 2022, compared to $3.1 million for the quarter ended March 31, 2021.

Net Loss: Marker reported a net loss of $9.9 million for the quarter ended March 31, 2022, compared to a net loss of $8.8 million for the quarter ended March 31, 2021.